在ST升高心肌梗塞中的冠状动脉内血栓溶解:系统性审查和元分析
Rajan Rehan1,2, Sohaib Virk3, Christopher C Y Wong4,5
1Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Heart (British Cardiac Society)
|June 26, 2024
概括
在ST升高心肌梗塞的初级穿皮冠状动脉干预期间的辅助冠状动脉血栓溶解显著减少了主要的不良心脏事件,并改善了心脏功能,而不会增加出血风险.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 不充分的微循环输液是急性ST升高心肌梗塞 (STEMI) 的常见并发症,尽管心上血流恢复了,导致预后不佳.
- 目前正在探索用于治疗微血管血栓的冠状动脉内 (IC) 血栓解压疗法,但现有的研究结果是矛盾的.
研究的目的:
- 评估在STEMI的初级皮肤穿透冠状动脉干预 (PCI) 期间进行的辅助IC血栓缓解疗法的疗效和安全性.
- 分析IC血栓溶解对主要心脏不良事件 (MACE) 和心肌 perfusion 的影响.
主要方法:
- 对六个电子数据库进行了全面的文献搜索,以确定相关的随机对照试验.
- 评估的主要结局是主要心脏不良事件 (MACE).
- 组合风险比率 (RR) 和加权平均差异 (WMD) 具有95%的置信区间 (CI) 被计算为元分析.
主要成果:
- 分析包括12项研究,涉及1915名患者.
- 辅助IC血栓溶解与MACE显著降低相关 (RR=0.65,95% CI 0.51至0.82) 和改善左心室喷射率 (WMD=1.87,95% CI 1.07至2.67).
- 亚组分析显示,非纤维素和中度纤维素特异性药物显著降低了MACE,但高纤维素特异性药物没有. 没有观察到死亡率或出血事件的显著差异.
结论:
- 在STEMI患者的初级PCI期间辅助IC血栓溶解改善了临床结果和心肌 perfusion.
- 治疗似乎不会增加出血事件的风险.
- 进一步的研究是有必要的,以优化血栓消毒剂和治疗方案的选择.
更多相关视频
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
9.3K
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.4K
相关概念视频
01:27Coronary Artery Disease V: Interprofessional Care
444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
01:30Acute Coronary Syndrome I: Introduction
2.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
943
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
943
01:30Acute Coronary Syndrome III: Diagnostic Studies
495
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
01:28Acute Coronary Syndrome IV: Interprofessional Care
522
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
01:26Angina IV: Management
493
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
493